相关实验视频
Updated: Sep 9, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
研究人工甜味剂对糖尿病管理和血糖控制的影响
Rukaiah Fatma Begum1, S Nirenjen2, Rapuru Rushendran2
1Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
Frontiers in nutrition
|August 28, 2025
概括
人工甜味剂可以通过提供帮助控制血糖和减少热量摄入的糖替代品来帮助糖尿病管理. 将AS纳入健康的生活方式可以改善血糖控制和胰岛素敏感性.
科学领域:
- 代谢性疾病
- 营养科学
- 内分泌学
背景情况:
- 糖尿病是一种慢性代谢疾病,对全球健康有重大影响.
- 有效的DM治疗需要医疗干预以及改变生活方式和饮食.
- 人工甜味剂是低热量糖替代品,对血糖的影响最小.
研究的目的:
- 探索人工甜味剂在糖尿病管理中的作用.
- 审查AS对血糖控制和胰岛素敏感性的疗效,安全性和长期影响.
- 研究AS对肠道微生物群和代谢结果的潜在影响.
主要方法:
- 在糖尿病管理中对AS进行的临床前和临床研究的全面审查.
- 分析AS机制,包括对胰岛素敏感性和葡萄糖代谢的影响.
- 评估AS对热量摄入,和肠道微生物群的影响.
主要成果:
- 像阿斯巴达姆,苏克拉洛斯和甜菜这样的药物对糖尿病患者的血糖控制有潜力.
- 可以减少卡路里摄入量,促进腹感,并支持血糖控制和胰岛素敏感性.
- 新出现的证据表明,AS可能会调节肠道微生物群,影响代谢结果.
结论:
- 当被整合到全面的生活方式中时,AS可以成为糖尿病管理的有益辅助.
- 了解潜在的风险,如改变口味感知和过度依赖,对于安全使用至关重要.
- 需要精准医学方法来根据个体的代谢反应量身定制AS.
相关概念视频
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Diabetes Mellitus: Overview and Type I Subtype
3.2K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Oral Hypoglycemic Agents: Sulfonylureas
320
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
320

